Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IGXT NASDAQ:TORC NASDAQ:ZFGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/ATORCresTORbio$6.55+1.9%$12.16$0.86▼$10.50$238.77M2.431.15 million shs274,305 shsZFGNZafgen$5.09+1.0%$18.47$0.62▼$2.76$190.72M0.27360,199 shs1.32 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%TORCresTORbio0.00%0.00%0.00%-8.65%+772.98%ZFGNZafgen0.00%0.00%0.00%+15.68%+76.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/ATORCresTORbio$6.55+1.9%$12.16$0.86▼$10.50$238.77M2.431.15 million shs274,305 shsZFGNZafgen$5.09+1.0%$18.47$0.62▼$2.76$190.72M0.27360,199 shs1.32 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%TORCresTORbio0.00%0.00%0.00%-8.65%+772.98%ZFGNZafgen0.00%0.00%0.00%+15.68%+76.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx Technologies 0.00N/AN/AN/ATORCresTORbio 0.00N/AN/AN/AZFGNZafgen 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/AN/AN/AN/AN/AN/AN/ATORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/AZFGNZafgen-$45.41M-$1.07N/AN/AN/AN/A-51.34%-34.55%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/AN/AN/ATORCresTORbioN/A20.6920.69ZFGNZafgen0.266.566.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/ATORCresTORbio46.19%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%TORCresTORbio11.80%ZFGNZafgen14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableTORCresTORbioN/A36.45 millionN/ANot OptionableZFGNZafgen3837.47 millionN/ANot OptionableZFGN, TORC, and IGXT HeadlinesRecent News About These CompaniesGSK/Sirtris compounds dogged by assay artifactsMay 21, 2024 | nature.comNTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMDiagnosing Diabetes: Not So SimpleNovember 2, 2023 | medscape.comMDo New Weight Loss Meds Mean the End of Bariatric Surgery?October 6, 2023 | medscape.comMPrader-Willi syndromeAugust 23, 2023 | pharmaphorum.comPThe Omnipod 5 System: Trial Results From ENDO 2021August 4, 2023 | medscape.comMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?July 5, 2023 | medscape.comMOral Semaglutide Brings GLP-1s to Primary CareMay 20, 2023 | medscape.comMClinical Trials - Different Phases of the trial News, Research and Latest UpdatesMay 20, 2023 | medindia.netMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital JournalMay 12, 2023 | news.google.comNWeight Loss and Obesity Management Market Insights With ... - Taiwan NewsMay 11, 2023 | news.google.comNGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern ExaminerMay 4, 2023 | news.google.comNWeight Loss and Obesity Management Market May See a Big Move ... - Digital JournalMay 2, 2023 | news.google.comNIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best StocksMay 2, 2023 | news.google.comNThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the CirculationApril 29, 2023 | medscape.comMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape ReferenceApril 21, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital JournalApril 20, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRApril 14, 2023 | news.google.comNNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMZFGN, TORC, and IGXT Company DescriptionsIntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 06/12/2026IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.resTORbio NASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.Zafgen NASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
